



PRAGUE
22-24 MAY 2025




INDUSTRY SESSIONS PROGRAMME BOOKLET

TABLE OF CONTENTS

Satellite Symposia Programme at a glance.....	4
Thursday, 22 May 2025.....	6
Friday, 23 May 2025.....	7
Friday, 23 May 2025.....	8

We invite you to discover the official industry sessions programmes of this year's EADV Symposium 2025 in Prague, Czech Republic.

Three satellite symposia are organised between 22 and 23 May 2025.

<p>A satellite symposium organised by our Platinum Sponsor UCB, that will focus on hidradenitis suppurativa and psoriasis</p>	 <p>Inspired by patients. Driven by science.</p>
<p>Expert faculty will share their approach and key clinical data used to overcoming key clinical challenges encountered when managing patients with moderate-to-severe AD. Be sure to join us and take control of your learning by selecting clinical challenges that are most relevant to you.</p>	
<p>A satellite symposium organised by La Roche-Posay Laboratoire Dermatologique, a brand of our Silver Sponsor L'Oréal Dermatological Beauty, that will focus on Acne</p>	

The satellite symposia will offer a unique opportunity to connect with key thought leaders, access information on emerging science, new products and innovative approaches on a wide range of current medical topics.

As a true platform for collaboration and progress, the EADV would like to thank all the sponsors for providing additional educational opportunities during the EADV Symposium 2025.

Satellite Symposia Programme at a glance

ROOM NAME	South Hall 1	South Hall 2
Thursday 22 May 2025		
12:45 – 13:45		SAT 02
		La Roche-Posay Laboratoire Dermatologique
Friday 23 May 2025		
12:45 – 13:45	SAT 04	SAT 05
	Pfizer	UCB

HCP only and Non Members (INDUSTRY)

Session open to all

Satellite symposia programme and faculty in particular

The Industry Session organiser is solely responsible for keeping all its Industry Session activities compliant with all relevant laws and regulations. EADV is not involved with or has any control over the content, quality, organisation, operation, or scientific integrity of the activity and materials provided by the industries. EADV is not involved in the selection of speakers, moderators, and other faculty.

Access to satellite symposia

As a multidisciplinary audience will be attending the EADV Symposium 2025, please make sure to select the right category: Healthcare Professionals (HCPs) or Non-Healthcare Professionals (NON-HCPs), during the registration process.


Access to any Industry Sessions where data or research on prescription medicines is presented will be limited to Healthcare Professionals (HCPs) and Non Members (INDUSTRY).

Industry Session organisers may limit participation to certain representative groups independently from EADV recommendations if deemed imperative to the achievement of the intended purpose of the Industry Session.

Satellite Symposia

Thursday, 22 May 2025

SATELLITE SYMPOSIUM

 12:45 – 13:45 CEST

 Open to all

 South Hall 2

La Roche-Posay Laboratoire Dermatologique



SAT 02		How to Optimize Acne Treatment?
SAT 02.01	12:45	Dermocosmetics in Acne: From Study Results to Clinical Practice Monika Arenbergerova (Prague, Czech Republic)
SAT 02.02	13:05	Targeting Acne with Key Active Ingredients Christos C. Zouboulis (Dessau, Germany)
SAT 02.03	13:25	Interactive case discussion Monika Arenbergerova (Prague, Czech Republic) Christos C. Zouboulis (Dessau, Germany)

Satellite Symposia

Friday, 23 May 2025

SATELLITE SYMPOSIUM

⌚ 12:45 – 13:45 CEST

👤 HCP ONLY

📍 South Hall 1

Pfizer




SAT 04		Ask the Experts: Optimizing Atopic Dermatitis Treatment With Abrocitinib Chair: Ignasi Figueras-Nart (Barcelona, Spain)
SAT 04.01	12:45	Welcome and Introductions Ignasi Figueras-Nart (Barcelona, Spain)
SAT 04.02	12:55	Clinical Challenge – Your Questions Answered Nina Magnolo (Münster, Germany) Ignasi Figueras-Nart (Barcelona, Spain)
SAT 04.03	13:35	Programme Summary and Audience Questions Ignasi Figueras-Nart (Barcelona, Spain)

Satellite Symposia

Friday, 23 May 2025

SATELLITE SYMPOSIUM

 12:45 – 13:45 CEST

 HCP ONLY

 South Hall 2

UCB



SAT 05		Dual inhibition of IL-17A and IL-17F in inflammatory diseases: Modifying disease outcomes in HS and PSO Chair: Petr Arenberger (Prague, Czech Republic)
SAT 5.01	12:45	Welcome and introductions Petr Arenberger (Prague, Czech Republic)
SAT 5.02	12:48	Across the spectrum: How can bimekizumab's dual inhibition translate to clinical outcomes in inflammatory diseases? Maria-Angeliki Gkini (London, United Kingdom)
SAT 5.03	12:58	Focus on HS: How can bimekizumab provide inflammatory control for patients? Monika Arenbergerova (Prague, Czech Republic)
SAT 5.04	13:13	Focus on PSO: How can bimekizumab's clinical evidence translate to real-world evidence? Petr Arenberger (Prague, Czech Republic)
SAT 5.05	13:23	Focus on PSO to PsA: How can early intervention impact outcomes for patients? Maria-Angeliki Gkini (London, United Kingdom)
SAT 5.05	13:33	Expert Q&A Petr Arenberger (Prague, Czech Republic) Monika Arenbergerova (Prague, Czech Republic) Maria-Angeliki Gkini (London, United Kingdom)
SAT 5.05	13:43	Conclusions and meeting close Petr Arenberger (Prague, Czech Republic)

A UCB Promotional Cross-Indication Symposium
at EADV Spring Symposium 2025

Dual inhibition of IL-17A and IL-17F in inflammatory diseases: Modifying disease outcomes in HS and PSO

 **Friday, 23rd May 2025**  **12:45–13:45 CEST**

 **South Hall 2, Prague Congress Centre**

This symposium will discuss insights into the mechanism of action of bimekizumab ▼ and translation to outcomes across the spectrum of inflammatory diseases, such as hidradenitis suppurativa (HS) and psoriasis (PSO).

Speakers



Prof Petr Arenberger

Symposium chair

Charles University,
Third Faculty of Medicine,
Czech Republic



Prof Monika Arenbergerova

Charles University,
Third Faculty of Medicine,
Czech Republic



Dr Maria-Angeliki Gkini

Barts Health NHS Trust,
UK

Agenda

Session

Welcome and introductions

Across the spectrum: How can bimekizumab's dual inhibition translate to clinical outcomes in inflammatory diseases?

Focus on HS: How can bimekizumab provide inflammatory control for patients?

Focus on PSO: How can bimekizumab's clinical evidence translate to real-world evidence?

Focus on PSO to PsA: How can early intervention impact outcomes for patients?

Expert Q&A

Conclusions and meeting close

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please refer to the Summary of Product Characteristics, available at:

https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf.

This is a promotional meeting and UCB drugs will be discussed during this meeting.
Intended for healthcare professionals only.

Bimekizumab is approved in the European Union for the treatment of adults with moderate to severe plaque psoriasis, active psoriatic arthritis, active axial spondyloarthritis and moderate to severe hidradenitis suppurativa.¹

1. Bimzelx® EU SmPC. https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf. Last accessed: March 2025.

© UCB Biopharma SRL, 2025. All rights reserved. Date of preparation: March 2025 EU-BK-2500040



Inspired by patients.
Driven by science.





We're inspired by a single vision:

Transforming patients' lives through science[®]

 Bristol Myers Squibb[®]

[bms.com](https://www.bms.com)

We are proud to support the EADV Symposium.

© 2024 Bristol-Myers Squibb Company. All rights reserved.